Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration
Randomized study in people · 2026
- What was studied
- 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
- Main finding
- At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).
Dry AMD mean retinal light sensitivity · +3.27 ± 1.03 dB with Retinalamin · −4.14 ± 2.11 dB with placebo · Day 720 · Between-arm difference in change +7.41 dB (p < 0.001)
Reported findings and study design
Randomized comparison with threshold microperimetry at 76 retinal locations using the Nidek MP-3. Follow-up visits ran from day 90 to day 720. Dry and wet measurements came from fellow eyes in the same participants.
Population or model 21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
Dose, route and schedule
The companion electroretinography paper describes eight 10-day intramuscular courses at 90-day intervals. The accessible abstracts leave the mass per dose unspecified.
Protocol source ↗ · Companion paper from the same journal supplement
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dry AMD mean retinal light sensitivity | +3.27 ± 1.03 dB with Retinalamin | −4.14 ± 2.11 dB with placebo · Day 720 · Between-arm difference in change +7.41 dB (p < 0.001) |
| Wet AMD mean retinal light sensitivity | The within-arm increase with Retinalamin was inconclusive (p = 0.302) | −3.57 ± 0.94 dB with placebo · Day 720 · Reported between-arm difference in change +5.57 dB (p < 0.001) |
| Dry AMD eyes without relative blind spots on testing | 27.3% to 100% with Retinalamin (p = 0.002) | All placebo eyes had relative blind spots by day 180 |
| Companion electroretinography report | The authors describe differences favoring Retinalamin across most electrical response measures. | Exact estimates for individual electrical endpoints require the full tables. |
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- The two supplement papers match on sample size, eye diagnoses, intervention and 720-day follow-up, and the microperimetry paper cites the electroretinography paper. They are treated as one cohort. The relationship to the larger RetinGero trial remains unconfirmed.
- The abstracts leave masking, withdrawals, other eye treatments and adverse-event counts unclear. The study results describe how the retina responded to testing. Effects on visual acuity and disease progression remain unclear.
Source details
Original journal report
Original Russian abstracts for the microperimetry and companion electroretinography reports.
Sources checked
Citation
V. V. Neroev, S. V. Milash. Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration Russian Ophthalmological Journal. 2026;19(4 Suppl):33–40.
Study source ↗ · DOI 10.21516/2072-0076-2026-19-4-supplement-33-40 · Bibliography entry · Link to this summary